JP7364555B2 - 新規ニコチン結合抗体 - Google Patents

新規ニコチン結合抗体 Download PDF

Info

Publication number
JP7364555B2
JP7364555B2 JP2020509479A JP2020509479A JP7364555B2 JP 7364555 B2 JP7364555 B2 JP 7364555B2 JP 2020509479 A JP2020509479 A JP 2020509479A JP 2020509479 A JP2020509479 A JP 2020509479A JP 7364555 B2 JP7364555 B2 JP 7364555B2
Authority
JP
Japan
Prior art keywords
nicotine
seq
chain sequence
light chain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020509479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531480A (ja
JP2020531480A5 (enExample
Inventor
カルニク，マシュー・ダブリュ
ティステッド，トーマス
ベルトラミネリ，ニコラ
ファロ，ステファニー
ビエソバ，ズザナ
フラー，スティーブ
レセージ，マーク・ジー
ペンテル，ポール
Original Assignee
ブリンク・バイオメディカル・エス・ア・エス
アンティドートゥ・セラピューティクス・インコーポレイテッド
ヘネピン・ヘルスケア・リサーチ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリンク・バイオメディカル・エス・ア・エス, アンティドートゥ・セラピューティクス・インコーポレイテッド, ヘネピン・ヘルスケア・リサーチ・インスティテュート filed Critical ブリンク・バイオメディカル・エス・ア・エス
Publication of JP2020531480A publication Critical patent/JP2020531480A/ja
Publication of JP2020531480A5 publication Critical patent/JP2020531480A5/ja
Application granted granted Critical
Publication of JP7364555B2 publication Critical patent/JP7364555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020509479A 2017-08-15 2018-08-14 新規ニコチン結合抗体 Active JP7364555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
US62/545,696 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2020531480A JP2020531480A (ja) 2020-11-05
JP2020531480A5 JP2020531480A5 (enExample) 2021-09-30
JP7364555B2 true JP7364555B2 (ja) 2023-10-18

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020509479A Active JP7364555B2 (ja) 2017-08-15 2018-08-14 新規ニコチン結合抗体

Country Status (11)

Country Link
US (2) US11440970B2 (enExample)
EP (2) EP4624496A3 (enExample)
JP (1) JP7364555B2 (enExample)
KR (1) KR102712005B1 (enExample)
CN (1) CN111432883B (enExample)
AU (1) AU2018317372B2 (enExample)
BR (1) BR112020002994A2 (enExample)
CA (1) CA3072767A1 (enExample)
ES (1) ES3041362T3 (enExample)
MX (1) MX2020001725A (enExample)
WO (1) WO2019036419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512549A (zh) * 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504893A (ja) 2007-11-29 2011-02-17 サイトス バイオテクノロジー アーゲー ヒト・モノクローナル・ニコチン特異的抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A3 (en) * 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251821A1 (en) 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
WO2003082329A2 (en) 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1963308A4 (en) 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
MX2010013583A (es) 2008-06-13 2011-05-19 Nabi Biopharmaceuticals Kit y metodo para dejar de fumar.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504893A (ja) 2007-11-29 2011-02-17 サイトス バイオテクノロジー アーゲー ヒト・モノクローナル・ニコチン特異的抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRUG METABOLISM AND DISPOSITION，2005年，Vol.33, No.7, pp.1056-1061
nature biotechnology，2009年，Vol.27, No.8, pp.767-771，ONLINE METHODS, SUPPLEMENTARY FIGURES
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS，2006年，Vol.317, No.2, pp.660-666
ファルマシア，2016年，Vol.52, No.4, pp.322-326

Also Published As

Publication number Publication date
US11440970B2 (en) 2022-09-13
AU2018317372B2 (en) 2025-06-26
CN111432883B (zh) 2024-10-01
MX2020001725A (es) 2020-08-20
EP3668598B1 (en) 2025-07-30
KR20200089255A (ko) 2020-07-24
US20200377616A1 (en) 2020-12-03
AU2018317372A1 (en) 2020-03-05
WO2019036419A1 (en) 2019-02-21
EP4624496A2 (en) 2025-10-01
JP2020531480A (ja) 2020-11-05
KR102712005B1 (ko) 2024-09-30
EP4624496A3 (en) 2025-12-17
CA3072767A1 (en) 2019-02-21
CN111432883A (zh) 2020-07-17
ES3041362T3 (en) 2025-11-11
US20230089068A1 (en) 2023-03-23
BR112020002994A2 (pt) 2020-08-11
EP3668598A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
De Villiers et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
Kosten et al. Immunotherapy for the treatment of drug abuse
Azzopardi et al. A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products
Royal College of Physicians of London. Tobacco Advisory Group Nicotine addiction in Britain: A report of the Tobacco Advisory Group of the Royal College of Physicians
ES3037632T3 (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
LeSage et al. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies
Hoogsteder et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial
RS65360B1 (sr) Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US20230089068A1 (en) Novel nicotine-binding antibodies
Escobar-Chávez et al. Targeting nicotine addiction: the possibility of a therapeutic vaccine
Vocci et al. Vaccines against nicotine: how effective are they likely to be in preventing smoking?
Rose Disrupting nicotine reinforcement: from cigarette to brain
Raleigh et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
Michael Owens et al. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction
CN113474363A (zh) 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
JP2021532761A (ja) 新規ニコチン分解酵素変異体
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
TW202126699A (zh) 用於抗類胰蛋白酶抗體之投藥
US20220267474A1 (en) Methods for improving circulation and treating cardiovascular disease
Pashmi Immunotherapy approach to combat nicotine addiction
Barbosa-Mendez et al. NIC6-TT Vaccine Attenuates Nicotine-Seeking and Expression of Nicotine-Induced Locomotor Sensitization in Rats
Zhang et al. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Like Agonist, Exendin-4-Fc
Shor Effective Treatments for Nicotine Addiction
Oliver Vaccination against cotinine as a potential approach to smoking cessation
Sidhpura Neurochemical interactions of nicotine and bupropion in the rat striatum

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231005

R150 Certificate of patent or registration of utility model

Ref document number: 7364555

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150